STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 90 filers reported holding STEMLINE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 11.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $10,251,000 | +17.9% | 965,245 | +15.6% | 3.69% | -8.1% |
| Q3 2019 | $8,695,000 | -23.7% | 835,245 | +12.2% | 4.02% | -5.0% |
| Q2 2019 | $11,402,000 | +11.4% | 744,245 | -6.5% | 4.23% | +11.9% |
| Q1 2019 | $10,232,000 | +134.4% | 796,245 | +35.9% | 3.78% | +39.5% |
| Q4 2018 | $4,366,000 | -41.5% | 585,930 | 0.0% | 2.71% | -23.6% |
| Q3 2018 | $7,459,000 | -5.1% | 585,930 | +18.9% | 3.54% | +17.4% |
| Q2 2018 | $7,862,000 | +4.6% | 492,930 | 0.0% | 3.02% | +3.0% |
| Q1 2018 | $7,517,000 | -2.2% | 492,930 | 0.0% | 2.93% | +8.2% |
| Q4 2017 | $7,690,000 | +278.6% | 492,930 | +169.5% | 2.71% | +242.7% |
| Q3 2017 | $2,031,000 | -51.3% | 182,930 | -59.6% | 0.79% | -50.1% |
| Q2 2017 | $4,168,000 | +48.6% | 453,000 | +37.3% | 1.58% | +47.5% |
| Q1 2017 | $2,805,000 | – | 330,000 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
| Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
| NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
| Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
| Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
| KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
| Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
| Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
| J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |